Navigation Links
Life Technologies Signs Collaborative Agreement with Structural Genomics Consortium to Develop First Antibody Master Set for Epigenetic Studies
Date:7/19/2012

CARLSBAD, Calif., July 19, 2012 /PRNewswire/ -- Life Technologies Corporation (NASDAQ: LIFE) today announced it has signed a collaborative partnership with the Structural Genomics Consortium (SGC), and several groups of leading expert scientists in antibody technology at the Universities of Chicago and Toronto, to generate a first-ever master set of quality epigenetic recombinant antibodies for use in disease-related research.  The first 58 of 200 highly-specific antibodies to be designed are now available to the scientific community.

Epigenetic regulatory proteins are involved in a wide variety of chronic diseases, such as cancer, and are the target of an explosive new field of drug discovery.  The ability to properly study most epigenetic changes, which determine which genes are "turned off and on," are determined by the effectiveness of one critical tool -- antibodies.  A lack of industry-wide standards for quality antibodies, however, has plagued the field for years and resulted in an influx of products on the market that do not perform as advertised.  The recombinant antibodies produced from the Life Technologies/SGC partnership address this important issue.

"The partnership is prepared to produce a set of 200 highly-specific, highly-sensitive antibodies that are validated for specific applications," says Dr. Aled Edwards, Director and CEO of SGC. "These 58 now being launched are the first step toward developing the defacto standard set of quality epigenetics antibodies that researchers can use for generations to come."

The recombinant antibodies are being developed by Life Technologies in partnership with the SGC, which comprises a network of more than 200 scientists from the University of Toronto and Oxford University, as well as six pharmaceutical companies, which include AbbVie, Eli Lilly, GlaxoSmithKline, Novartis, Pfizer and Takeda.  These recombinant antibodies are renewable, meaning they are identical in performance from one lot to the next.  They are validated for consistent performance across applications for which they are intended, including immunoprecipitation.  This represents a significant improvement over existing antibodies in the market today.

Validation data and community reviews of the 58 recombinant antibodies can be found on Life Technologies' website and on 1DegreeBio.org, the world's largest open-access antibody database.  The release of the new epigenetics-targeted antibodies coincides with the launch of 1DegreeBio's new Epigenetics Portal, where epigenetics researchers can find targets, tools and product-data specific to their research.

"These reagents reflect a strong commitment from both public and private partners to address a long-standing quality issue in the community," says Alex Hodgson, Managing Director of 1DegreeBio.  "1DegreeBio is excited to support these and future reagents, and be the venue to measure their impact."

"The availability of high-quality research tools, such as Life Technologies' antibodies, will enable scientists to explore this completely new layer of biology and push the boundaries of our understanding of human disease, and facilitate the discovery of novel therapeutic targets," said Mark Stevenson, President and COO of Life Technologies.  "Our partnership with SGC in this pioneering endeavor demonstrates Life Technologies' commitment to provide the most innovative products that meet the needs of the global scientific community."

About The Structural Genomics Consortium (SGC)

Located at the Universities of Toronto and Oxford, the not-for-profit organization supports the discovery of new medicines by carrying out open access research in structural and chemical biology.  More than 200 researchers in academia and in six pharmaceutical companies collaborate within SGC to accomplish these goals.  The SGC is funded by the Canadian Institutes for Health Research, Genome Canada, the Ontario's Ministry of Economic Development and Innovation, Canadian Foundation for Innovation, the Wellcome Trust, AbbVie, Eli Lilly, GlaxoSmithKline, Novartis, Pfizer and Takeda.  More information is available at www.thesgc.org.

About Life Technologies

Life Technologies Corporation (NASDAQ: LIFE) is a global biotechnology company with customers in more than 160 countries using its innovative solutions to solve some of today's most difficult scientific challenges. Quality and innovation are accessible to every lab with its reliable and easy-to-use solutions spanning the biological spectrum with more than 50,000 products for agricultural biotechnology, translational research, molecular medicine and diagnostics, stem cell-based therapies, forensics, food safety and animal health. Its systems, reagents and consumables represent some of the most cited brands in scientific research including: Ion Torrent™, Applied Biosystems®,  Invitrogen™, GIBCO®, Ambion®, Molecular Probes®, Novex®, and TaqMan®. Life Technologies employs approximately 10,400 people and upholds its ongoing commitment to innovation with more than 4,000 patents and exclusive licenses. LIFE had sales of $3.7 billion in 2011. Visit us at our website: http://www.lifetechnologies.com.

Life Technologies' Safe Harbor Statement

This press release includes forward-looking statements about our anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies' plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words "believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and the like, and/or future tense or conditional constructions ("will," "may," "could," "should," etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.

(Logo: http://photos.prnewswire.com/prnh/20110216/MM49339LOGO)

Life Technologies Contact
Patty Zamora
760-476-7818
patty.zamora@lifetech.com

Structural Genomics Consortium
Arij Al Chawaf, PhD
416-854-2745
arij.alchawaf@thesgc.org 

 


'/>"/>
SOURCE Life Technologies Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Acquisition of Navigenics Expands Life Technologies Capabilities in Diagnostics
2. Medisafe 1 Technologies Corp has of Today Acquired 3,100,000 Shares and Continues to Acquire Shares Under its $1MM Stock Repurchase Program of 10MM Shares up to 10 Cents a Share to Facilitate its On-going Acquisitions Activity Plan
3. Dehaier Medical Receives Software Copyrights for Four Proprietary Technologies
4. CSS Health Technologies Hires Industry Leader as New Senior Vice President of Sales
5. Ancor and Merit acquire Uplift Technologies for Carex Health Brands
6. Ultra Clean Holdings, Inc. Completes Strategic Merger with Advanced Integration Technologies
7. Drug Delivery Technologies Show Promise of Improving Clinical Outcomes for Patients at PODD: Partnership Opportunities in Drug Delivery Conference
8. MicroVention Announces First Patient Enrollment In Clinical Trial To Compare Coiling Technologies For Treating Brain Aneurysms
9. Response to U.S. Supreme Courts Healthcare Decision by Michael Zamagias, Chairman, TeleTracking Technologies
10. Lifeline Biotechnologies, Inc. Receives Patent Award, a Device for Breast Tissue Temperature Analysis for Determining Cancer Conditions
11. Updated: LHA Life Sciences & Medical Technologies Virtual Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... 2016 --> ... "Fetal (Labor & Delivery) and Neonatal Care Equipment Market ... Oximeter, Phototherapy/Jaundice Management Devices, CPAP, Capnograph, & Resuscitator) - ... studies the global market over the forecast period of ... 6.28 Billion in 2015 and is poised to grow ...
(Date:2/4/2016)... -- For hospitals considering enrollment in the Federal 340B ... program, the Health Resources and Services Administration,s (HRSA) recent ... , could have significant impact on plans and operations, ... Essential Insights , Daniel Neal, director ... Mega-Guidance,s key proposed changes, including a new requirement that ...
(Date:2/4/2016)... CITY, Calif. , Feb. 4, 2016 /PRNewswire/ ... "Company") today announced it has entered into a ... Exchange Commission (SEC) fully resolving the SEC,s investigation ... Act (FCPA).  Under the terms of the settlement ... of $12.8 million, including disgorgement, pre-judgment interest and ...
Breaking Medicine Technology:
(Date:2/5/2016)... Ontario (PRWEB) , ... February 05, 2016 , ... After ... Scarborough General Hospital Burn Unit, plastic and cosmetic surgeon Dr. Wayne Carman transitioned to ... Scarborough Hospital. He successfully completed his first three-year term as chief and began a ...
(Date:2/5/2016)... ... February 05, 2016 , ... Regular gym users know the ... to wait longer to access the treadmills. It’s a predictable trend. After the excesses ... weight and get in shape by joining gyms, starting new walking or running routines, ...
(Date:2/5/2016)... ... February 05, 2016 , ... Dr. Justin Scott and Dr. ... Annual No Cost Dental Day to individuals in need. The event is scheduled to ... No Cost Dental Day is to provide dental care to community members in need. ...
(Date:2/5/2016)... ... 05, 2016 , ... Health and wellness is a topic that should concern ... they are experiencing an illness. Migraines are a severe form of a headache and ... would not wish the pain on their worst enemy, the feeling can last for ...
(Date:2/5/2016)... CA (PRWEB) , ... February 05, 2016 , ... –This ... on the benefits of having a tankless water heater. To view the report, ... water heaters: tank and tankless. While each has their pros and cons, the type ...
Breaking Medicine News(10 mins):